A Double-blind, Randomized, Placebo-controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MK-1654 in Pre-Term and Full-Term Infants
Phase of Trial: Phase I/II
Latest Information Update: 14 Jan 2020
Price : $35 *
At a glance
- Drugs MK-1654 (Primary)
- Indications Respiratory syncytial virus infections
- Focus Adverse reactions
- Sponsors Merck Sharp & Dohme
- 26 Aug 2019 Planned End Date changed from 12 Apr 2021 to 11 Apr 2022.
- 26 Aug 2019 Planned primary completion date changed from 12 Apr 2021 to 11 Apr 2022.
- 26 Aug 2019 Status changed from active, no longer recruiting to recruiting.